SEP 26, 2023 9:00 AM PDT

Comparison of multiplexed platforms for serum cytokine detection in COVID-19 patients

Sponsored by: Alamar Biosciences

Event Date & Time
Date: September 26, 2023
Time: 9:00am PDT, 11:00am CDT, 12:00pm EDT
Alamar NULISAseq is a novel commercial platform for highly multiplexed analysis of soluble proteins using a modified proximity ligation assay. We compared Luminex, Olink, and NULISAseq platforms for detection of cytokines and related inflammatory markers in sera from 25 patients with COVID-19 and 8 healthy controls. We analyzed detectability of common targets, correlations between platforms, and identification of differentially expressed targets in COVID-19 patients (versus healthy controls, over time, and with disease severity). We found the highest proportion of detectable targets with NULISAseq, and best correlations between NULISAseq and Olink. Correlations were often better for targets with high detectability. NULISAseq also identified the largest number of significant changes over time in longitudinal COVID-19 samples. Olink identified slightly more differentially expressed targets between healthy and COVID-19 samples, but some of these were, paradoxically, low in detectability in Olink. All three assays were similar in their ability to differentiate COVID-19 severity levels at hospital admission. Overall, our results suggest that NULISAseq is a highly sensitive assay, with good correlation
Learning Objectives
  • To understand the methodology used by major multiplexed immunoassay platforms, and the inherent pros and cons of each.
  • To describe the differences in detectability between assay platforms and how this relates to correlations between platforms.
  • To relate these assay differences to their ability to detect differential protein expression in COVID-19 patients.
Webinars will be available for unlimited on-demand viewing after live event.

You May Also Like
Loading Comments...